Ghigo E - Search Results

1

Ghrelin and des-acyl ghrelin both inhibit isoproterenol-induced lipolysis in rat adipocytes via a non-type 1a growth hormone secretagogue receptor.

Muccioli G, Pons N, Ghè C, Catapano F, Granata R, Ghigo E. Muccioli G, et al. Among authors: ghigo e. Eur J Pharmacol. 2004 Sep 13;498(1-3):27-35. doi: 10.1016/j.ejphar.2004.07.066. Eur J Pharmacol. 2004. PMID: 15363972

2

Effects of direct and indirect acetylcholine receptor agonists on growth hormone secretion in humans.

Mazza E, Ghigo E, Boffano G, Valetto M, Maccario M, Arvat E, Bellone J, Procopio M, Müller EE, Camanni F. Mazza E, et al. Among authors: ghigo e. Eur J Pharmacol. 1994 Mar 11;254(1-2):17-20. doi: 10.1016/0014-2999(94)90364-6. Eur J Pharmacol. 1994. PMID: 8206111

3

Short-term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging.

Ghigo E, Arvat E, Gianotti L, Grottoli S, Rizzi G, Ceda GP, Boghen MF, Deghenghi R, Camanni F. Ghigo E, et al. Eur J Endocrinol. 1996 Oct;135(4):407-12. doi: 10.1530/eje.0.1350407. Eur J Endocrinol. 1996. PMID: 8921821 Clinical Trial.

4

Growth hormone-releasing peptides.

Ghigo E, Arvat E, Muccioli G, Camanni F. Ghigo E, et al. Eur J Endocrinol. 1997 May;136(5):445-60. doi: 10.1530/eje.0.1360445. Eur J Endocrinol. 1997. PMID: 9186261 Review.

5

Identification of a pituitary growth hormone-releasing peptide (GHRP) receptor subtype by photoaffinity labeling.

Ong H, McNicoll N, Escher E, Collu R, Deghenghi R, Locatelli V, Ghigo E, Muccioli G, Boghen M, Nilsson M. Ong H, et al. Among authors: ghigo e. Endocrinology. 1998 Jan;139(1):432-5. doi: 10.1210/endo.139.1.5811. Endocrinology. 1998. PMID: 9421445

6

Specific receptors for synthetic GH secretagogues in the human brain and pituitary gland.

Muccioli G, Ghè C, Ghigo MC, Papotti M, Arvat E, Boghen MF, Nilsson MH, Deghenghi R, Ong H, Ghigo E. Muccioli G, et al. Among authors: ghigo e, ghigo mc. J Endocrinol. 1998 Apr;157(1):99-106. doi: 10.1677/joe.0.1570099. J Endocrinol. 1998. PMID: 9614363

7

Orally active growth hormone secretagogues: state of the art and clinical perspectives.

Ghigo E, Arvat E, Camanni F. Ghigo E, et al. Ann Med. 1998 Apr;30(2):159-68. doi: 10.3109/07853899808999399. Ann Med. 1998. PMID: 9667794 Free article. Review.

8

Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans.

Ghigo E, Gianotti L, Arvat E, Ramunni J, Valetto MR, Broglio F, Rolla M, Cavagnini F, Müller EE. Ghigo E, et al. J Clin Endocrinol Metab. 1999 Jan;84(1):285-90. doi: 10.1210/jcem.84.1.5386. J Clin Endocrinol Metab. 1999. PMID: 9920097 Clinical Trial.

9

Tyr-Ala-Hexarelin, a synthetic octapeptide, possesses the same endocrine activities of Hexarelin and GHRP-2 in humans.

Arvat E, Di Vito L, Lanfranco F, Broglio F, Giordano R, Benso A, Muccioli GP, Deghenghi R, Ghigo E. Arvat E, et al. Among authors: ghigo e. J Endocrinol Invest. 1999 Feb;22(2):91-7. doi: 10.1007/BF03350886. J Endocrinol Invest. 1999. PMID: 10195374 Clinical Trial.

10

Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans.

Bisi G, Podio V, Valetto MR, Broglio F, Bertuccio G, Del Rio G, Arvat E, Boghen MF, Deghenghi R, Muccioli G, Ong H, Ghigo E. Bisi G, et al. Among authors: ghigo e. J Endocrinol Invest. 1999 Apr;22(4):266-72. doi: 10.1007/BF03343555. J Endocrinol Invest. 1999. PMID: 10342360 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

869 results

Search Page

Filters